Abstract:Transcription factors (TFs) specifically bind to DNA, recruit cofactor proteins and modulate target gene expression, rendering them essential roles in the regulation of numerous biological processes. Meanwhile, mutated or dysregulated TFs are involved in a variety of human diseases. As multiple signaling pathways ultimately converge at TFs, targeting these TFs directly may prove to be more specific and cause fewer side effects, than targeting the upfront conventional targets in these pathways. All these features together endue TFs with great potential and high selectivity as therapeutic drug targets. However, TFs have been historically considered "undruggable", mainly due to their lack of structural information, especially about the appropriate ligand-binding sites and protein-protein interactions, leading to relatively limited choices in the TF-targeting drug design. In this review, we summarize the recent progress of TF-targeting drugs and highlight certain strategies used for targeting TFs, with a number of representative drugs that have been approved or in the clinical trials as examples. Various approaches in targeting TFs directly or indirectly have been developed. Common direct strategies include aiming at defined binding pockets, proteolysis-targeting chimaera (PROTAC), and mutant protein reactivation. In contrast, the indirect ones comprise inhibition of protein-protein interactions between TF and other proteins, blockade of TF expression, targeting the post-translational modifications, and targeting the TF-DNA interactions. With more comprehensive structural information about TFs revealed by the powerful cryo-electron microscopy technology and predicted by machine-learning algorithms, plus more efficient compound screening platforms and a deeper understanding of TF-disease relationships, the development of TF-targeting drugs will certainly be accelerated in the near future.

Targeting Post-Translational Modification of Transcription Factors As Cancer Therapy.

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Targeting transcription factors in cancer — from undruggable to reality

Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy

Targeting Transcription Factors for Cancer Treatment

Regulating tumor suppressor genes: post-translational modifications

Current Strategies and Progress for Targeting the “undruggable” Transcription Factors

Advances in targeting ‘undruggable’ transcription factors with small molecules

Advances in post-translational modifications of proteins and cancer immunotherapy

Post-translational modifications: The potential ways for killing cancer stem cells

Small-Molecule Approaches to Target Transcription Factors

Protein post-translational modifications in the regulation of cancer hallmarks

Protein Posttranslational Modification in Stemness Remodeling and Its Emerging Role as a Novel Therapeutic Target in Gastrointestinal Cancers

Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy

The Role of Transcription Factors in the Crosstalk Between Cancer-Associated Fibroblasts and Tumor Cells.

Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy

Advances in the role of membrane-bound transcription factors in carcinogenesis and therapy

Role of Post-Translational Modifications in Colorectal Cancer Metastasis

ATF family members as therapeutic targets in cancer: From mechanisms to pharmacological interventions

Intricate effects of post-translational modifications in liver cancer: mechanisms to clinical applications

Targeting Tumor Suppressor Genes for Cancer Therapy